# In silico screening of FDA-approved drugs for elimination of senescent cells via senescence-associated anti-apoptotic pathway inhibition

Source: [Biological sciences : nature.com subject feeds](https://www.nature.com/articles/s41598-026-78564-5) · 2026-11-19 · Life
Page: https://themorning.science/story/in-silico-screening-of-fda-approved-drugs-for-elimination-of-senescent-cells-via-b517e43426f69bef
Kind: research · Impact: low

## In brief

- The study is an in silico screen of FDA-approved drugs.
- It aims to find drugs that eliminate senescent cells.
- The approach works by inhibiting senescence-associated anti-apoptotic pathways.

## Why it matters

It proposes a computational route to repurpose approved drugs as senolytics, which could speed up testing of candidates that target senescent cells. The source provides only the title, so the results are not known.

## Coverage

- [In silico screening of FDA-approved drugs for elimination of senescent cells via senescence-associated anti-apoptotic pathway inhibition](https://www.nature.com/articles/s41598-026-78564-5) — Biological sciences : nature.com subject feeds, 2026-11-19

Tags: senescence, senolytics, drug repurposing, in silico screening, apoptosis

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
